Dose Insider / Glossary / ATTAIN-1

ATTAIN-1The trial behind the Foundayo weight-loss pill

Updated November 20, 2026 · 3 min read · Wharton et al., N Engl J Med 2025; FOUNDAYO label

ATTAIN-1 is the main phase 3 trial of orforglipron, the daily GLP-1 pill later approved as Foundayo. It enrolled 3,127 adults with obesity and without diabetes and gave them orforglipron 6 mg, 12 mg or 36 mg, or placebo, once a day for 72 weeks alongside diet and activity advice. Weight fell by 7.5%, 8.4% and 11.2% on the three doses, against 2.1% on placebo.

54.6%Orforglipron 36 mg, 10% or more, share reaching each weight loss
Share reaching each weight lossATTAIN-1, 36 mg vs placebo, week 72, %ORFORGLIPRON 36 MG10% or more54.6%15% or more36.0%20% or more18.4%PLACEBO10% or more12.9%20% or more2.8%Share reaching each weightlossATTAIN-1, 36 mg vs placebo, week 72, %ORFORGLIPRON 36 MG10% or more54.6%15% or more36.0%20% or more18.4%PLACEBO10% or more12.9%20% or more2.8%

Average weight change −11.2% on 36 mg, −2.1% on placebo.

On this page

It was published in the New England Journal of Medicine in 2025.1

How the trial was run

ATTAIN-1 was multinational, randomized and double-blind. Participants were assigned in a 3:3:3:4 ratio to the three doses and placebo. The main outcome was the percentage change in weight at week 72.1 The Foundayo label describes the participants as adults with a body mass index of 30 or more, or 27 to under 30 with at least one weight-related condition. It names high cholesterol, high blood pressure, sleep apnea and heart disease as examples.2

The trial used an investigational formulation. The label reports its doses as the equivalent Foundayo doses: 6, 12 and 36 mg in the trial correspond to 5.5, 9 and 17.2 mg of Foundayo.2

What it found

Wharton et al., 2025.1

In its own analysis the Foundayo label gives losses of 7.4%, 8.3% and 11.1%, from starting weights of about 102 to 104 kg, and reports nausea in up to 35% against 10% on placebo across its two trials.2

Why a pill matters

Orforglipron is a small molecule rather than a peptide, so it is absorbed from the gut without the strict rules of the semaglutide tablets. The Foundayo label says it can be taken with or without food.1,2 The semaglutide tablets, by contrast, must be taken fasting with a little water and a 30-minute wait. In its own 64-week trial the Wegovy 25 mg tablet lowered weight by 13.6%.3 The two pills were not compared directly. Our page on how to take the Wegovy pill covers the semaglutide routine.

Before ATTAIN-1

A phase 2 trial published in 2023 had enrolled 272 adults who started at an average of 108.7 kg. At week 36, weight fell by 9.4% to 14.7% across dose groups, against 2.3% on placebo. Stomach and gut events, mostly during the dose climb, led 10% to 17% to stop.4 ATTAIN-1 then ran twice as long, 72 weeks, in more than ten times as many people.

How it is taken now

On the Foundayo label, the dose starts at 0.8 mg a day and rises every 30 days or more, through 2.5, 5.5, 9 and 14.5 mg, to at most 17.2 mg. Because a liver enzyme, CYP3A4, breaks the drug down, some other medicines lower its dose limit.2

The ATTAIN program

ATTAIN-2, the companion trial, tested the drug in 1,613 adults with type 2 diabetes, where weight fell by up to 9.6% on the label's equivalent top dose, against 2.5% on placebo.2,5 As with the injected GLP-1 medicines, the loss was smaller in people with diabetes.

Limits

The trial was funded by Eli Lilly, the maker of orforglipron, and enrolled only people without diabetes. It lasted 72 weeks, so it does not show long-term results.1

Sources

  1. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. Funded by Eli Lilly; NCT05869903. doi:10.1056/NEJMoa2511774
  2. FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company; DailyMed, version published August 13, 2026; sections 2, 6.1 and 14. dailymed.nlm.nih.gov
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2 and 14. accessdata.fda.gov
  4. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 2023;389:877-888. doi:10.1056/NEJMoa2302392
  5. ClinicalTrials.gov record NCT05872620 (ATTAIN-2), sponsor Eli Lilly and Company; read November 20, 2026. clinicaltrials.gov

Related analyses

Log each tablet and your weight, and see how your curve compares.

Open Dose Insider